Circulating Galectins -2, -4 and -8 in Cancer Patients Make Important Contributions to the Increased Circulation of Several Cytokines and Chemokines That Promote Angiogenesis and Metastasis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Jan 4

PMID 24384681

Citations 41

Authors

C Chen

C A Duckworth

B Fu

D M Pritchard

J M Rhodes

L-G Yu

Affiliations

Soon will be listed here.

Abstract

Background: Circulating concentrations of the cytokines interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF) and chemokines monocyte chemotatic protein 1 (MCP-1)/CCL2 and growth-regulator oncogene α (GROα)/chemokine C-X-C motif ligand 1 are commonly increased in cancer patients and they are increasingly recognised as important promoters, via divergent mechanisms, of cancer progression and metastasis.

Methods: The effect of galectins-2, -4 and -8, whose circulating levels are highly increased in cancer patients, on endothelial secretion of cytokines was assessed in vitro by cytokine array and in mice. The relationship between serum levels of galectins and cytokines was analysed in colon and breast cancer patients.

Results: Galectins-2, -4 and -8 at pathological concentrations induce secretion of G-CSF, IL-6, MCP-1 and GROα from the blood vascular endothelial cells in vitro and in mice. Multiple regression analysis indicates that increased circulation of these galectins accounts for 41∼83% of the variance of these cytokines in the sera of colon and breast cancer patients. The galectin-induced secretion of these cytokines/chemokines is shown to enhance the expression of endothelial cell surface adhesion molecules, causing increased cancer-endothelial adhesion and increased endothelial tubule formation.

Conclusion: The increased circulation of galectins -2, -4 and -8 in cancer patients contributes substantially to the increased circulation of G-CSF, IL-6 and MCP-1 by interaction with the blood vascular endothelium. These cytokines and chemokines in turn enhance endothelial cell activities in angiogenesis and metastasis.

Citing Articles

Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis.

Han H, Su H, Lv Z, Zhu C, Huang J Biomedicines. 2025; 13(1).

PMID: 39857769 PMC: 11759815. DOI: 10.3390/biomedicines13010185.

Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.

Carvalho L, Assis R, Montenegro C, da Rosa M, Pereira M, Pitta M Int J Mol Sci. 2025; 25(24.

PMID: 39769262 PMC: 11676459. DOI: 10.3390/ijms252413499.

Vascular galectins in tumor angiogenesis and cancer immunity.

Thijssen V Semin Immunopathol. 2024; 46(1-2):3.

PMID: 38990363 PMC: 11239785. DOI: 10.1007/s00281-024-01014-9.

Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.

Elliott Jr W, Tsung A, Guda M, Velpula K Am J Cancer Res. 2024; 14(2):774-795.

PMID: 38455415 PMC: 10915327.

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer.

Torres-Martinez S, Calabuig-Farinas S, Gallach S, Mosqueda M, Munera-Maravilla E, Sirera R Int J Mol Sci. 2023; 24(24).

PMID: 38139416 PMC: 10743468. DOI: 10.3390/ijms242417587.

References

Bresalier R, Byrd J, Tessler D, Lebel J, Koomen J, Hawke D . A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology. 2004; 127(3):741-8. DOI: 10.1053/j.gastro.2004.06.016. View

Ara T, DeClerck Y . Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010; 46(7):1223-31. PMC: 2917917. DOI: 10.1016/j.ejca.2010.02.026. View

Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S . Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000; 6(4):1389-93. View

Luan J, Shattuck-Brandt R, Haghnegahdar H, OWEN J, Strieter R, Burdick M . Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol. 1997; 62(5):588-97. DOI: 10.1002/jlb.62.5.588. View

Ara T, Song L, Shimada H, Keshelava N, Russell H, Metelitsa L . Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009; 69(1):329-37. PMC: 2761219. DOI: 10.1158/0008-5472.CAN-08-0613. View

Chin A, Wang S . Cytokines driving breast cancer stemness. Mol Cell Endocrinol. 2013; 382(1):598-602. DOI: 10.1016/j.mce.2013.03.024. View

Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes J . Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer. 2010; 9:154. PMC: 2911446. DOI: 10.1186/1476-4598-9-154. View

Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama H . Serum level of galectin-3 in human bladder cancer. J Med Invest. 2008; 55(1-2):127-32. DOI: 10.2152/jmi.55.127. View

Nangia-Makker P, Ochieng J, Christman J, Raz A . Regulation of the expression of galactoside-binding lectin during human monocytic differentiation. Cancer Res. 1993; 53(20):5033-7. View

10.

Chen C, Duckworth C, Zhao Q, Pritchard D, Rhodes J, Yu L . Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 2013; 19(7):1693-704. PMC: 3618858. DOI: 10.1158/1078-0432.CCR-12-2940. View

11.

Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H . Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 2002; 50(3):392-401. PMC: 1773143. DOI: 10.1136/gut.50.3.392. View

12.

Bandapalli O, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M . Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine. 2011; 57(1):46-53. DOI: 10.1016/j.cyto.2011.10.019. View

13.

Yu L, Andrews N, Zhao Q, McKean D, Williams J, Connor L . Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2006; 282(1):773-81. DOI: 10.1074/jbc.M606862200. View

14.

Barrow H, Rhodes J, Yu L . Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol (Dordr). 2012; 36(1):9-13. DOI: 10.1007/s13402-012-0109-1. View

15.

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X . Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010; 107(50):21248-55. PMC: 3003076. DOI: 10.1073/pnas.1015855107. View

16.

Xie L, Ni W, Chen X, Xiao M, Chen B, He S . The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 2012; 138(6):1035-43. DOI: 10.1007/s00432-012-1178-2. View

17.

John C, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis G . Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res. 2003; 9(6):2374-83. View

18.

Barrow H, Guo X, Wandall H, Pedersen J, Fu B, Zhao Q . Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 2011; 17(22):7035-46. DOI: 10.1158/1078-0432.CCR-11-1462. View

19.

Ren J, Agata N, Chen D, Li Y, Yu W, Huang L . Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004; 5(2):163-75. PMC: 4217165. DOI: 10.1016/s1535-6108(04)00020-0. View

20.

Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K . Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?. Gastric Cancer. 2010; 13(4):212-21. DOI: 10.1007/s10120-010-0568-x. View